title: Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.
abstract: Immunotherapy and chemotherapy are generally effective against small tumors in animal models of cancer. However, these treatment regimens are generally ineffective against large, bulky tumors. We have found that a multimodality treatment regimen using DNA vaccination in combination with chemotherapeutic agent epigallocatechin-3-gallate (EGCG), a compound found in green tea, is effective in inhibiting large tumor growth. EGCG was found to induce tumor cellular apoptosis in a dose-dependent manner. The combination of EGCG and DNA vaccination led to an enhanced tumor-specific T-cell immune response and enhanced antitumor effects, resulting in a higher cure rate than either immunotherapy or EGCG alone. In addition, combined DNA vaccination and oral EGCG treatment provided long-term antitumor protection in cured mice. Cured animals rejected a challenge of E7-expressing tumors, such as TC-1 and B16E7, but not a challenge of B16 7 weeks after the combined treatment, showing antigen-specific immune responses. These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than single-modality treatments.
authors.affiliation: Laboratory of Infection and Immunology, Graduate School of Medicine, Korea University, Gyeonggi-Do, South Korea.
authors.forename: Tae Heung
authors.initials: TH
authors.lastname: Kang
authors.forename: Jin Hyup
authors.initials: JH
authors.lastname: Lee
authors.forename: Chung Kil
authors.initials: CK
authors.lastname: Song
authors.forename: Hee Dong
authors.initials: HD
authors.lastname: Han
authors.forename: Byung Cheol
authors.initials: BC
authors.lastname: Shin
authors.forename: Sara I
authors.initials: SI
authors.lastname: Pai
authors.forename: Chien-Fu
authors.initials: CF
authors.lastname: Hung
authors.forename: Cornelia
authors.initials: C
authors.lastname: Trimble
authors.forename: Jong-Seok
authors.initials: JS
authors.lastname: Lim
authors.forename: Tae Woo
authors.initials: TW
authors.lastname: Kim
authors.forename: T-C
authors.initials: TC
authors.lastname: Wu
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D002392:Catechin / Q000031:analogs & derivatives* / Q000276:immunology / Q000494:pharmacology; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000276:immunology / Q000628:therapy* / Q000821:virology; D051379:Mice; D008810:Mice, Inbred C57BL; D009856:Oncogene Proteins, Viral / Q000276:immunology; D050725:Papillomavirus E7 Proteins; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology / Q000494:pharmacology*
chemical_list: D000951:Antigens, Neoplasm; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D019444:Vaccines, DNA; C059731:oncogene protein E7, Human papillomavirus type 16; D002392:Catechin; C045651:epigallocatechin gallate